Spatiotemporally Engineered POSS Nanoplatform for Multi-Organelle-Targeted Synergistic Photothermal-Chemo-Immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41540595.
- Also identified by DOI 10.1002/adhm.202505008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor heterogeneity and immunosuppression limit the efficacy of conventional immunotherapy. Here, we introduce a spatiotemporally engineered nanoplatform (CAP/CyOH@NPs) that achieves multi-organelle targeting in tumor cells through POSS-based nanoconfinement. The rigid POSS cage co-encapsulates a photothermal agent (CyOH) and chemotherapeutic prodrug (capecitabine), enabling stable, simultaneous localization to lysosomes, mitochondria, and the endoplasmic reticulum-independent of pH or membrane potential. This subcellular precision enhances photothermal conversion (53.4%) and amplifies immunogenic cell death via coordinated organelle stress. When combined with PD-L1 blockade, the platform remodels the tumor immune microenvironment and suppresses both primary and distant tumors in a 4T1 breast cancer model. This work establishes a new paradigm for engineering nanomedicines with organelle-level specificity, offering a versatile strategy to overcome resistance in precision oncology.
Medical subject headings
- Immunotherapy
- Organosilicon Compounds
- Photothermal Therapy
- Nanoparticles
- Organelles